Array Biopharma (ARRY) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018
May 9, 2018 8:00 AM EDTBOULDER, Colo., May 9, 2018 /PRNewswire/ --Â Array BioPharma Inc., (Nasdaq: ARRY) today reported results for its third quarter of fiscal 2018 and provided an update on the progress of its key clinical development programs.
"Preparations for the anticipated U.S. launch of encorafenib and binimetinib in BRAF-mutant melanoma are well underway," said Ron Squarer, Chief Executive Officer. "We are... More



